Halozyme Therapeutics (HALO) Fundamental Analysis: Revenue, Earnings & Valuation

6.45 / 10

Outperform

Fundamentally, HALO rates Outperform with a 6.5/10 quality score. Strengths include PB‑ROE, cash‑to‑market, asset‑to‑market and strong YoY revenue growth. Weak points are high income‑tax ratio, low revenue‑to‑market and modest gross margin. Overall fundamentals are satisfactory.

Analysis Checks(7/10)

Revenue-MV

Value-0.64

Score1/3

Weight19.52%

1M Return4.95%

Total operating revenue (YoY growth rate %)

Value37.55

Score3/3

Weight5.04%

1M Return1.54%

Inventory turnover ratio

Value1.44

Score2/3

Weight-3.64%

1M Return-1.21%

Gross profit margin (%)

Value83.62

Score0/3

Weight-18.94%

1M Return-7.24%

PB-ROE

Value2.24

Score3/3

Weight40.61%

1M Return9.74%

Income tax / Total profit (%)

Value32.13

Score1/3

Weight-1.49%

1M Return-0.50%

Fixed assets turnover ratio

Value32.74

Score2/3

Weight-1.72%

1M Return-0.51%

Cost of sales ratio (%)

Value16.38

Score2/3

Weight-12.44%

1M Return-4.42%

Asset-MV

Value-0.55

Score2/3

Weight50.07%

1M Return12.22%

Cash-MV

Value0.10

Score2/3

Weight23.00%

1M Return5.94%

Is HALO undervalued or overvalued?

HALO scores 6.45/10 on fundamentals and holds a Discounted valuation at present. Backed by its 153.59% ROE, 22.69% net margin, 24.16 P/E ratio, 156.86 P/B ratio, and -24.57% earnings growth, these metrics solidify its Outperform investment rating.